Amphastar Pharmaceuticals, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Amphastar Pharmaceuticals, Inc. (AMPH) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $30.29 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $35.65, a 4.96% decline year-over-year.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $37.51, a 4.28% increase year-over-year.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $35.97, a 15.25% increase year-over-year.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $31.21, a 81.56% increase year-over-year.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $33.74, a 5.54% decline from fiscal 2024.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $35.72, a 15.90% increase from fiscal 2023.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $30.82, a 57.57% increase from fiscal 2022.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $19.56, a 14.59% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $30.29 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $35.65 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $33.74 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $33.40 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $33.40 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $37.51 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $35.72 10-K · filed 2025-03-03 | |||
| 2024-09-30 | $35.10 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $33.45 10-Q · filed 2024-08-09 | |||
| 2024-03-31 | $35.97 10-Q · filed 2024-05-10 | |||
| 2023-12-31 | $30.82 10-K · filed 2024-02-29 | |||
| 2023-09-30 | $29.60 10-Q · filed 2023-11-08 | |||
| 2023-06-30 | $29.60 10-Q · filed 2023-08-09 | |||
| 2023-03-31 | $31.21 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $19.56 10-K · filed 2023-03-01 | |||
| 2022-09-30 | $19.56 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $19.30 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $17.19 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | $17.07 10-K · filed 2022-03-11 | |||
| 2021-09-30 | $17.02 10-Q · filed 2021-11-09 | |||
| 2021-06-30 | $15.94 10-Q · filed 2021-08-09 | |||
| 2021-03-31 | $15.67 10-Q · filed 2021-05-07 | |||
| 2020-12-31 | $16.42 10-K · filed 2021-03-15 | |||
| 2020-09-30 | $16.53 10-Q · filed 2020-11-06 | |||
| 2020-06-30 | $16.53 10-Q · filed 2020-08-07 | |||
| 2020-03-31 | $18.82 10-Q · filed 2020-05-11 | |||
| 2019-12-31 | $17.84 10-K · filed 2020-03-16 | |||
| 2019-09-30 | $18.47 10-Q · filed 2019-11-08 | |||
| 2019-06-30 | $18.90 10-Q · filed 2019-08-09 | |||
| 2019-03-31 | $18.45 10-Q · filed 2019-05-10 | |||
| 2018-12-31 | $13.84 10-K · filed 2019-03-15 | |||
| 2018-09-30 | $13.47 10-Q · filed 2018-11-09 | |||
| 2018-06-30 | $13.21 10-Q · filed 2018-08-09 | |||
| 2018-03-31 | $13.02 10-Q · filed 2018-05-10 | |||
| 2017-12-31 | $13.67 10-K · filed 2018-03-14 | |||
| 2017-09-30 | $13.57 10-Q · filed 2017-11-09 | |||
| 2017-06-30 | $13.59 10-Q · filed 2017-08-09 | |||
| 2017-03-31 | $12.97 10-Q · filed 2017-05-10 | |||
| 2016-12-31 | $13.50 10-K · filed 2017-03-15 | |||
| 2016-09-30 | $13.48 10-Q · filed 2016-11-09 | |||
| 2016-06-30 | $13.46 10-Q · filed 2016-08-09 | |||
| 2016-03-31 | $14.03 10-Q · filed 2016-05-10 | |||
| 2015-12-31 | $13.27 10-K · filed 2016-03-15 | |||
| 2015-09-30 | $13.76 10-Q · filed 2015-11-13 | |||
| 2015-06-30 | $13.69 10-Q · filed 2015-08-13 | |||
| 2015-03-31 | $14.21 10-Q · filed 2015-05-14 | |||
| 2014-12-31 | $15.74 10-K · filed 2016-03-15 | |||
| 2014-09-30 | $12.11 10-Q · filed 2014-11-13 | |||
| 2014-06-30 | $12.01 10-Q · filed 2014-08-13 | |||
| 2013-12-31 | $12.88 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |